In recent years, the application of proteomics technology has developed rapidly. In the past two years alone, the top international journals Cell, Nature, and Science have cumulatively published more than a hundred research results on proteomics and protein modification proteomics technologies. With the continuous breakthroughs in related research technologies, proteins, as the carriers of life activities, will be able to help scientific research and even clinical personnel study and understand the mechanisms of cancer occurrence in a more comprehensive and in-depth manner, and proteomics is also expected to become a new approach to precision medicine in the post-genomic era. He Fuchu, Academician of the Chinese Academy of Sciences and Researcher at the Academy of Military Medical Sciences of the PLA, once said: "If the invention of antibiotics triggered the first generation of medical treatment technology revolution, and the development of imaging and molecular medicine triggered the second generation of medical diagnostic technology revolution, then precision medicine driven by proteomics is bound to bring about the third generation of medical revolution—the unification of precise diagnosis and precision treatment."

      As a leader in clinical proteomics, ProteinT has been deeply engaged since 2014 in gene-protein-metabolite multi-omics research centered on proteomics, and has continuously made breakthroughs in independent R&D technologies. Based on years of technological accumulation, ProteinT's independently developed next-generation liquid biopsy technology has achieved the identification and quantitative analysis of 4000+ blood proteins from a single sample within one hour. It is currently developing and implementing a product pipeline covering early screening and early diagnosis of common cancers such as liver cancer, lung cancer, gastric cancer, esophageal cancer, colorectal cancer, and pancreatic cancer, as well as pan-cancer and chronic diseases such as cardiovascular and cerebrovascular diseases, tumor recurrence monitoring, and drug companion diagnostics. By integrating high-throughput automated liquid biopsy solutions, it has laid a solid foundation for liquid biopsy in directions such as medical health and pharmaceutical industry R&D.

Photo of the interior of the ProteinT laboratory

      CloudHealth Medical (Yunjian Medical), also a leading enterprise in precision medicine, has extensive experience in multi-omics and artificial intelligence clinical and translational research. Domestically, it has key laboratories and operation centers in multiple locations including Shanghai, Tianjin, Hangzhou, Nanjing, Chengdu, and Hong Kong. It has also reached an OEM cooperation strategy with Thermo Fisher to jointly promote the popularization of its Orbitrap mass spectrometry platform in the fields of precision medicine and big health in China, possessing strong resource advantages.

CloudHealth Medical Orbitrap mass spectrometry platform

       This strategic cooperation between ProteinT and CloudHealth Medical fully integrates the resource advantages of both parties, combining ProteinT's breakthrough technologies in proteomics and other fields with CloudHealth Medical's resource advantages in high-precision mass spectrometry platforms, to accelerate the application of proteomics and mass spectrometry in clinical precision medicine and greatly enhance the implementation and commercialization of ProteinT's series of new product pipelines.

       Breakthroughs in innovative technologies constantly rewrite human history. Cancer, known as the number one killer of human health, has more than 3 million patients and more than 220 billion yuan in treatment costs each year in China. ProteinT and CloudHealth Medical joining hands to promote the clinical application of new proteomics technologies is expected to bring more convenient and economical screening and diagnostic methods, improve the early screening and early diagnosis rate of cancer, reduce treatment costs, and alleviate the suffering and economic burden of numerous cancer and cardiovascular and cerebrovascular disease patients. The implementation of related proteomics liquid biopsy products will further drive domestic proteomics technology and applications to lead internationally.